In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2326-2332

  Bartizal, Ken ^a   Gill, Charles J ^a   Abruzzo, George K ^a   Flattery, Amy M ^a   Kong, Li ^a   Scott, Patricia M ^a   Smith, Jeffrey G ^a   Leighton, Claire E ^a   Bouffard, Aileen ^a   Dropinski, James F ^a   Balkovec, James ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; LIPOPEPTIDE; PNEUMOCANDIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; FUNGICIDAL ACTIVITY; HEMOLYSIS; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL;

EID: 17044455920     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2326     Document Type: Article

References (40)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, D. Krupa, V. B. Pikounis, H. Kropp, and K. Bartizal. 1995. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 39:1077-1081.
2. Abruzzo, G. K., A. Flattery, C. Gill, J. Smith, H. Kropp, and K. Bartizal. 1993. Evaluation of water-soluble lipopeptides in a mouse model of disseminated aspergillosis, abstr. 355, p. 184. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Boufard, J. M. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin MK-0991 (L-743,872): efficacy in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob. Agents Chemother. 41:2333-2338.
4. Annaisse, E., G. P. Body, and H. Kantarjian. 1989. New spectrum of fungal infections in patients with cancer. Rev. Infect. Dis. 11:369-378.
5. Annaisse, E., G. P. Body, and M. G. Rinaldi. 1989. Emerging fungal pathogens. Eur. J. Clin. Infect. Dis. 8:323-330.
6. Bartizal, K., A. Flattery, L. Lynch, C. Pacholok, C. J. Gill, H. Rosen, P. Scott, and H. Kropp. 1996. In vitro preclinical evaluation studies with pneumocandin antifungal L-743,872, abstr. F32, p. 105. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Bartizal, K., G. Abruzzo, C. Trainor, D. Krupa, K. Nollstadt, D. Schmatz, R. Schwartz, M. Hammond, J. Balkovec, and F. Vanmiddlesworth. 1992. In vitro antifungal activities and in vivo efficacies of 1,3-β-D-glucan synthesis inhibitors L-671329, L-646991, tetrahydroechinocandin B, and L-687781, a papulacandin. Antimicrob. Agents Chemother. 36:1648-1657.
8. Bartizal, K., G. Abruzzo, and D. Schmatz. 1993. The pneumocandins: biological activity of the pneumocandins, p. 421-455. In J. Rippon and R. A. Fromtling (eds.), Cutaneous fungal infections. Marcel Dekker, Inc., New York, N.Y.
9. Beaulieu, D., J. Tang, D. J. Zeckner, and T. J. Parr. 1993. Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-β-D-glucan synthase. FEMS Microbiol. Lett. 108:133-138.
10. Bernard, E. M., T. Ishimaru, and D. Armstrong. 1996. Low doses of pneumocandin, L-743,872, are effective for prevention and treatment in an animal model of pulmonary aspergillosis, abstr. F39, p. 105. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Boken, D. J., S. Swindells, and M. G. Rinaldi. 1993. Fluconazole-resistant Candida albicans. Clin. Infect. Dis. 17:1018-1021.
12. Bouffard, F. A., J. F. Dropinski, J. M. Balkovec, R. M. Black, M. L. Hammond, K. H. Nollstadt, and S. Dreikorn. 1996. L-743,872 a novel antifungal lipopeptide: synthesis and structure-activity relationships of new aza-substituted pneumocandins, abstr. F27, p. 104. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Cox, G. M., and J. R. Perfect. 1993. Fungal infections. Curr. Opin. Infect. Dis. 6:422-426.
14. Denning, D. W. 1994. Evolving etiology of fungal infection in the 1990s. Infect. Dis. Clin. Pract. 3(2):S50-S55.
15. Douglas, C., J. Marrinan, J. Curotto, J. Onishi, and M. Kurtz. 1992. Activity of a new echinocandin, L-688,786 against filamentous fungi, abstr. A-41, p. 7. In Abstracts of 92nd General Meeting of the American Society for Microbiology 1992. American Society for Microbiology, Washington, D.C.
16. Espinel-Ingroff, A., C. W. Kish, T. M. Kerkering, R. A. Fromtling, K. Bartizal, J. N. Galgiani, K. Villareal, M. A. Pfaller, T. Gerarden, M. G. Rinaldi, and A. Fothergill. 1992. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J. Clin. Microbiol. 30:3138-3145.
17. Gordee, R. S., D. J. Zeckner, L. F. Ellis, A. L. Thakkar, and L. C. Howard. 1984. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J. Antibiot. 37:294-309.
18. Guiot, H. F. L., W. E. Fibbe, and J. W. van't Wout. 1994. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empiric therapy and prophylaxis. Clin. Infect. Dis. 18:525-532.
19. Hajdu, R., B. Pelak, J. Sundelof, R. Thompson, H. Rosen, and H. Kropp. 1997. Pharmacokinetics of L-743,872 in the mouse, rat, rhesus and chimpanzee, abstr. F44, p. 107. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. Hector, R. F. 1993. Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev. 6:1-21.
21. Hewitt, W. 1977. The agar diffusion assay, p. 17-20. In Microbiological assay: an introduction of quantitative principles and evaluation. Academic Press, Inc., New York, N.Y.
22. Hitchcock, C. A., G. W. Pye, P. F. Troke, E. M. Johnson, and D. W. Warnock. 1993. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37:1962-1965.
23. Huang, A., F. Edwards, E. M. Bernard, D. Armstrong, and H. J. Schmitt. 1990. In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 9:697-699.
24. James, P. G., R. Cherniak, R. G. Jones, C. A. Stortz, and E. Reiss. 1990. Cell-wall glucans of Cryptococcus neoformans CAP 67. Carbohydr. Res. 198: 23-38.
25. Komshian, S. V., A. K. Uwaydah, J. D. Sobel, and L. R. Crane. 1989. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics and evaluation of factors influencing outcome. Rev. Infect. Dis. 11:379-390.
26. Krogstad, D. J., and R. C. Mollering. 1986. Antimicrobial combinations, p. 537-578. In V. Lorian (ed.), Antibiotics in laboratory medicine, 2nd ed. The Williams & Wilkins Co., Baltimore, Md.
27. Kurtz, M., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
28. Kurtz, M. B., C. Douglas, J. Marrinan, K. Nollstadt, J. Onishi, S. Dreikorn, J. Milligan, M. L. Hammond, R. A. Zambias, G. Abruzzo, K. Bartizal, O. B. McManus, and M. L. Garcia. 1994. Increased antifungal activity of L-733560, a water soluble semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob. Agents Chemother. 38:2750-2757.
29. Najvar, L., A. Fothergill, M. Luther, and J. Graybill. 1996. Efficacy of L-743,872 (872) in murine disseminated candidiasis, abstr. F38, p. 106. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
30. Najvar, L., J. Graybill, E. Montalbo, F. Barchiesi, and M. Luther. 1996. Evaluation of L-743,872 (872) in the treatment of murine histoplasmosis, abstr. F43, p. 107. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
31. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth antifungal susceptibility testing of yeast. Tentative standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
32. Nelson, P. W., M. Lozano-Chiu, and J. H. Rex. 1996. In vitro activity of L-743,872 against putatively amphotericin B (AmB) and fluconazole-resistant Candida isolates, abstr. F28, p. 104. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
33. Peterson, E. M., R. J. Hawley, and R. A. Calderone. 1976. An ultrastructural analysis of protoplast-spheroplast induction in Cryptococcus neoformans. Can. J. Clin. Microbiol. Infect. Dis. 8:1067-1070.
34. Powles, M. A., J. Anderson, P. Liberator, and D. M. Schmatz. 1996. Efficacy of semisynthetic pneumocandin analog L-743,872 against Pneumocystis carinii in murine models, abstr. F42, p. 107. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
35. Ruhnke, M., A. Eigler, I. Tennagen, B. Geiseler, E. Engelmann, and M. Trautmann. 1994. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J. Clin. Microbiol. 32:2092-2098.
36. Schmatz, D., D. C. McFadden, P. Liberator, J. Anderson, and M. A. Powles. 1993. Evaluation of new semisynthetic pneumocandins against Pneumocystis carinii in the immunocompromised rat, abstr. 356, p. 184. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
37. Smith, J. G., G. K. Abruzzo, C. J. Gill, A. M. Flattery, L. Kong, H. Rosen, H. Kropp, and K. Bartizal. 1996. Evaluation of pneumocandin L-743,872 in neutropenic mouse models of disseminated candidiasis and aspergillosis, abstr. F41, p. 107. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
38. Swartz, M. N. 1994. Hospital acquired-infections: diseases with increasingly limited therapies. Proc. Natl. Acad. Sci. USA 91:2420-2427.
39. Tkacz, J. 1992. Glucan biosynthesis in fungi and its inhibition, p. 495-523. In J. A. Sutcliffe and N. H. Georgopapadakou (ed.), Emerging targets in antibacterial and antifungal chemotherapy. Routledge, Chapman & Hall, New York, N.Y.
40. Vazquez, J. A., D. Boikov, M. E. Lynch, and J. D. Sobel. 1996. In vitro antifungal activity of L-743,872, a new pneumocandin, against sensitive and resistant Torulopsis and Candida species, abstr. F42, p. 107. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.